Xspray Pharma invites investors, analysts and media to a conference call following the company’s receipt of a Complete Response Letter, CRL, from the U.S. Food and Drug Administration, FDA, in relation to the company’s New Drug Application, NDA for Dasynoc. The receipt of the CRL was announced in a press release earlier today, 19 August 2026.
Date: Thursday, 20 August 2026
Time: 09:00 CEST
Speaker: Blake Leitch, CEO of Xspray Pharma
Language: English
The conference call will be hosted by Xspray Pharma’s CEO Blake Leitch, who will comment on the content of the CRL, the main remaining questions from the FDA and the company’s view of the next steps in the process. The presentation will be held in English and will conclude with a Q&A session.
If you wish to participate via webcast, please use the following link: https://xspray.events.inderes.com/press-conference-aug-2026
Via the webcast, you are able to ask written questions.
If you wish to ask questions verbally via the teleconference, please register using the following link: https://events.inderes.com/xspray/press-conference-aug-2026/dial-in
After registration, you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.